尿激酶是一种纤溶酶原激活剂，临床上用于治疗血栓。
Urokinase, a human plasminogen activator, is used clinically to promote the dissolution of thrombi.
晚期6小时纤溶酶原激活剂没有减少梗死体积，而是更坏出血性转换。
Late 6-hour tPA did not decrease infarction but instead worsened hemorrhagic conversion.
纤溶酶原激活剂在血栓性疾病和出血性疾病的诊断具有潜在应用价值。
The potential application of PA as diagnostic tools in diseases of the thrombi.
目的观察应用重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死的效果。
Objective to observe the effect of recombinant tissue plasminogen activator in the treatment of acute myocardial infarction.
目的探讨急性冠状动脉综合征患者内皮组织纤溶酶原激活剂储备功能的变化规律。
Objective To study the changes of the endothelial tissue plasminogen activator reserve capacity in patients with acute coronary syndromes.
目的：研究重组纤溶酶原激活剂抑制剂-2基因表达对纤维肉瘤细胞超微结构的影响。
The effect of recombinant PAI-2 on the ultrastructure of fibrosarcoma-transplanted tumor was investigated in this study.
本文用尿激酶(UK)和人体组织型纤溶酶原激活剂(t - PA)进行了兔髂股动脉血栓实验性溶解的对照研究。
The thrombolytic effect was compared between urokinase (UK) and human tissue plasminogen activator (t-PA) in rabbits with experimental iliofemoral artery thrombus.
公众应当认识到，只有食品和药物管理局核准的中风治疗药物(组织型纤溶酶原激活剂)必须在症状出现的3小时内给予。
The public should be aware that the only Food and Drug Administration-approved stroke treatment medication must be administered within 3 hours of symptom onset.
从脑片染色结果及给药后不同时间点大鼠血液中纤溶酶原激活剂和其抑制剂的含量变化显示用该工艺纯化的蚓激酶有较好的溶栓作用。
The EFE purified through the process mentioned above has high specific activity and good effect in treating cerebral ischemia. Concerntration oft-PA and PAI, in respect of the rats in…
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
据报道，纳豆激酶有和胞浆素一样的可直接分解纤维蛋白的生物特性，或者增强尿激酶原和t—PA(人组织型纤溶酶原激活剂)的活性。
According to reports, Nattokinase has plasmin-like bio-characteristic that lyses fibrin directly, or increases activity of pro-urokinase and t-PA (Tissue Plasminogen Activator).
应用推荐